U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C24H25ClN2O.ClH
Molecular Weight 429.382
Optical Activity UNSPECIFIED
Defined Stereocenters 4 / 4
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of RTI-336

SMILES

Cl.CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)C3=CC=C(Cl)C=C3)C4=CC(=NO4)C5=CC=C(C)C=C5

InChI

InChIKey=IZMZEMAKFSYLMD-SXBQIKTFSA-N
InChI=1S/C24H25ClN2O.ClH/c1-15-3-5-17(6-4-15)21-14-23(28-26-21)24-20(16-7-9-18(25)10-8-16)13-19-11-12-22(24)27(19)2;/h3-10,14,19-20,22,24H,11-13H2,1-2H3;1H/t19-,20+,22+,24-;/m0./s1

HIDE SMILES / InChI

Molecular Formula C24H25ClN2O
Molecular Weight 392.921
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 4 / 4
E/Z Centers 0
Optical Activity UNSPECIFIED

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

RTI-336 was developed as a selective dopamine transporter (DAT) inhibitor. It is known that DAT inhibitors have been developed as a promising treatment approach for cocaine dependence. RTI-336 can be a useful adjunct in the treatment of cocaine dependence because preclinical data has shown that this drug inhibits DAT with a slower onset and offset rate than cocaine and with less abuse potential and psychomotor stimulant activity. RTI-336 participated in phase I clinical trial where it showed the excellent safety and tolerability, and thus further studies in humans are warranted.

Approval Year

PubMed

PubMed

TitleDatePubMed
A Double-Blind, Placebo-Controlled Trial Demonstrating the Safety, Tolerability, and Pharmacokinetics of Single, Escalating Oral Doses of RTI-336.
2018
Effects of dopamine transporter selective 3-phenyltropane analogs on locomotor activity, drug discrimination, and cocaine self-administration after oral administration.
2006-12-28
Development of the dopamine transporter selective RTI-336 as a pharmacotherapy for cocaine abuse.
2006-03-24

Sample Use Guides

RTI-336 drug product is formulated as hard, white, gelatin capsules. The dosage levels are 0.3, 1.0, and 3.0 mg (Cohort 1) and 6.0, 12.0, and 20.0 mg (Cohort 2). Subjects will receive a single dose of the study drug on study day 1.
Route of Administration: Oral
Substance Class Chemical
Created
by admin
on Mon Mar 31 19:32:29 GMT 2025
Edited
by admin
on Mon Mar 31 19:32:29 GMT 2025
Record UNII
667440B6Z7
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
RTI 336
Preferred Name English
RTI-336
Common Name English
8-AZABICYCLO(3.2.1)OCTANE, 3-(4-CHLOROPHENYL)-8-METHYL-2-(3-(4-METHYLPHENYL)-5-ISOXAZOLYL)-, HYDROCHLORIDE (1:1), (1R,2S,3S,5S)-
Common Name English
RTI 4229-336
Code English
8-AZABICYCLO(3.2.1)OCTANE, 3-(4-CHLOROPHENYL)-8-METHYL-2-(3-(4-METHYLPHENYL)-5-ISOXAZOLYL)-, MONOHYDROCHLORIDE, (1R,2S,3S,5S)-
Common Name English
8-AZABICYCLO(3.2.1)OCTANE, 3-(4-CHLOROPHENYL)-8-METHYL-2-(3-(4-METHYLPHENYL)-5-ISOXAZOLYL)-, MONOHYDROCHLORIDE, (1R-(EXO,EXO))-
Common Name English
Code System Code Type Description
FDA UNII
667440B6Z7
Created by admin on Mon Mar 31 19:32:29 GMT 2025 , Edited by admin on Mon Mar 31 19:32:29 GMT 2025
PRIMARY
PUBCHEM
11524766
Created by admin on Mon Mar 31 19:32:29 GMT 2025 , Edited by admin on Mon Mar 31 19:32:29 GMT 2025
PRIMARY
MESH
C506585
Created by admin on Mon Mar 31 19:32:29 GMT 2025 , Edited by admin on Mon Mar 31 19:32:29 GMT 2025
PRIMARY
CAS
204069-50-1
Created by admin on Mon Mar 31 19:32:29 GMT 2025 , Edited by admin on Mon Mar 31 19:32:29 GMT 2025
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE